drugset / Trial / NCT02354898
A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, phase 1 dose escalation study of BBI503 monotherapy, or BBI503 in combination with Sorafenib. This study population is adult patients with advanced solid tumors in monotherapy, or adult patients with advanced hepatocellular carcinoma in combination therapy.
Timeline
- Start
- 2015-03
- Primary completion
- 2018-10
- Completion
- 2018-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMCASERTIB | Small molecule | — | — |
| Background | Sorafenib | Small molecule | 400 mg | — |